Charles Schwab Investment Management Inc. Has $82.65 Million Stock Position in Solventum Co. (NYSE:SOLV)

Charles Schwab Investment Management Inc. lessened its stake in Solventum Co. (NYSE:SOLV) by 10.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,185,461 shares of the company’s stock after selling 136,479 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Solventum were worth $82,650,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of SOLV. Banco Santander S.A. acquired a new stake in shares of Solventum in the third quarter valued at approximately $215,000. Thompson Siegel & Walmsley LLC bought a new position in Solventum in the 3rd quarter valued at $7,719,000. Cypress Capital Group increased its stake in shares of Solventum by 9.1% in the 3rd quarter. Cypress Capital Group now owns 20,706 shares of the company’s stock valued at $1,444,000 after buying an additional 1,719 shares during the period. Landscape Capital Management L.L.C. bought a new stake in shares of Solventum during the third quarter worth $227,000. Finally, Intech Investment Management LLC bought a new position in Solventum in the third quarter valued at about $317,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Morgan Stanley boosted their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. The Goldman Sachs Group boosted their price target on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Wells Fargo & Company reduced their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, August 9th. Wolfe Research began coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating for the company. Finally, Stifel Nicolaus assumed coverage on Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and a consensus target price of $68.00.

Solventum Trading Up 1.4 %

SOLV opened at $72.48 on Thursday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a fifty day simple moving average of $70.51 and a 200 day simple moving average of $62.47.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.